|
⚲
|
| Keyboard |
| Eversept Partners LP
✚
|
|
|---|---|
| CRD # | 282358 |
| SEC # | 801-108771 |
| CIK # | 0001697013 |
| AUM | 2,651.0 M (2026-03-31) |
| Employees | 10 (50% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 212-271-4200 |
| Address | 444 Madison Avenue New York, NY 10022 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Tue, 28 Jul 2026 | Eversept Partners LP Makes New $2.47 Million Investment in LB Pharmaceuticals Inc $LBRX — MarketBeat |
| Tue, 28 Jul 2026 | Eversept Partners LP Has $104.05 Million Holdings in Abivax SA Sponsored ADR $ABVX — MarketBeat |
| Tue, 28 Jul 2026 | Eversept Partners LP Takes $917,000 Position in Sonida Senior Living, Inc. $SNDA — MarketBeat |
| Tue, 28 Jul 2026 | Eversept Partners LP Has $2.69 Million Stock Holdings in Relay Therapeutics, Inc. $RLAY — MarketBeat |
| Tue, 28 Jul 2026 | 585,680 Shares in Omega Healthcare Investors, Inc. $OHI Bought by Eversept Partners LP — MarketBeat |
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
ITEM 5 – FEES AND COMPENSATION
Unless otherwise provided in the applicable side letters, Eversept is compensated for its advisory services
with respect to each Fund as follows:
o The GHC Funds – Class A/Class F-B: Eversept receives a management fee, payable
quarterly in advance, equal to 0.4375% (1.75% per annum) of the value of each investor’s
capital account or shares. Eversept also receives an annual incentive allocation or fee equal
to 20% of net profits of the GHC Fund subject to the return of any amount in the loss
recovery account.
o The GHC Funds – Class F-A: Eversept receives a management fee, payable quarterly in
advance, equal to 0.3125% (1.25% per annum) of the value of each investor’s capital
account or shares. Eversept also receives an annual incentive allocation or fee equal to
15% of net profits of the GHC Fund subject to the return of any amount in the loss recovery
account. Class F-A terms revert to Class A terms effective January 1, 2027.
o The GHC Funds – Class L-A: Eversept receives a management fee, payable monthly in
advance, equal to 0.0833% (1.00% per annum) of the value of each investor’s capital
account or shares. Eversept also receives an annual incentive allocation or fee equal to
20% of net profits of the GHC Fund subject to a hurdle and the return of any amount in the
loss recovery account.
o The GHC Funds – Class M-A/Class M-B1/Class-B2: Individually negotiated.
o The GHC Funds – Class S/Class L-S: Individually negotiated.
o The EGF Funds – Class L: Eversept receives a management fee, payable monthly in
advance, equal to 0.0833% (1.00% per annum) of the value of each investor’s capital
account or shares. Eversept also receives an annual incentive allocation or fee equal to
20% of net profits of the EGF Fund subject to a hurdle and the return of any amount in the
loss recovery account.
o The ELS Funds – Individually negotiated.
o Other Accounts – Individually negotiated.
Class F-A and Class F-B of the GHC Funds are founder classes and are closed to new investments. Class
M-A, Class M-B1 and Class-M-B2 of the GHC Funds are classes of interests/shares offered to clients of a
third-party selling agent. Class L-A and Class L-S of the GHC Funds and Class L of the EGF Funds are
classes of interests/shares that invest in long-only portfolios (see additional details relating to these classes
in the relevant fund documents).
Eversept or its affiliates deduct fees from the Eversept Funds’ assets. The management fee is generally
paid to Eversept from the Eversept Funds either quarterly or monthly in advance (adjusted for subscriptions
during the calendar quarter). In the event of a withdrawal/redemption request made other than as of the last
day of a month or quarter, as applicable, Eversept or its affiliates will not refund management fees for the
remaining period. The incentive allocation or fee, as applicable, is generally allocated or paid to Eversept,
its affiliates or designated person(s) at the end of each fiscal year (adjusted for any withdrawals or
redemptions during the year) or upon any investor redemption in an amount based on the portion of the
investment redeemed.
Eversept’s fees with respect to the Eversept Funds are generally not negotiable. Notwithstanding the
foregoing, Eversept has elected to waive or offer reduced fees to certain investors in one or more Eversept
Funds, including to investors that are affiliates or employees of Eversept, members of the immediate
families of such persons and trusts or other entities for their benefit, or for certain large or strategic investors.
Investors in certain classes of interest in the Eversept Funds are generally limited in their ability to terminate
their participation in a Fund. In addition to other redemption and transfer restrictions that are described in
each Eversept Fund’s governing documents, certain classes of interests in the Eversept Funds limit
redemptions such that redemption requests are subject to a quarterly gate equal to a percentage of an
investor’s capital account balance. To the extent a redemption request exceeds such limit, the excess will
be deferred and treated as a request for redemption on each of the next successive quarterly redemption
dates until fully satisfied.
In addition to the management fee and incentive allocation or fee described above, each Eversept Fund shall
bear its own expenses. Such expenses vary by Eversept Fund, but generally include the following (note,
however, that this is not a complete list of expenses): (A) all expenses incurred in connection with the
ongoing offer and sale of interests of the Eversept Fund, including, but not limited to, expenses (including
compliance related expenses) incurred by the GP or Eversept pursuant to applicable law in connection with
the offer and sale of such Interests in any jurisdiction, (B) all operating expenses of the Eversept Fund such
as tax preparation fees, governmental fees and taxes, insurance, administrator fees (including trade
affirmation and trade break reconciliation fees), advisory committee member fees, communications with
investors, and ongoing legal, compliance costs of the Eversept Fund (including, without limitation,
expenses relating to preparation of regulatory filings (such as Schedule 13Fs, Schedule 13Hs, Schedule
13Gs, Schedule 13Ds, Form PF and Form D/Bluesky) and of third-party compliance consultants to assist
with such filings), accounting, auditing, bookkeeping, consulting and other professional fees and expenses;
... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
ITEM 7 – TYPES OF CLIENTS
Eversept provides investment advisory services to the Advisory Clients. The minimum capital
contributions or account balances in the Advisory Clients are as follows:
o The GHC Funds – Class A/Class F-A/Class F-B/Class L-A/Class L-S/Class S: $5
million initial capital contribution and $1 million additional capital contribution, each
subject to the sole discretion of GP I or the GHC Fund board to accept lower amounts.
Additionally, GP I may disallow the partial withdrawal of capital by any investor, if as a
result of, or prior to, such withdrawal, the aggregate balance of such investor’s capital
account(s) would be less than $100,000.
o The GHC Funds – Class M-A/Class M-B1/Class M-B2: Individually negotiated.
o The EGF Funds – Class L: $5 million initial capital contribution and $1 million additional
capital contribution, each subject to the sole discretion of GP III or the EGF Fund board to
accept lower amounts. Additionally, GP III may disallow the partial withdrawal of capital
by any investor, if as a result of, or prior to, such withdrawal, the aggregate balance of such
investor’s capital account(s) would be less than $100,000.
o The ELS Funds – Individually negotiated.
o Other Accounts – Individually negotiated. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| United Therapeutics Corp | 0.2 | ||
| Abivax Sa | 0.1 | ||
| GlaxoSmithKline PLC | 0.1 | ||
| Vera Therapeutics Inc | 0.1 | ||
| Natera Inc | 0.1 | ||
| Syndax Pharmaceuticals Inc | 0.1 | ||
| Celldex Therapeutics Inc | 0.1 | ||
| Vaxcyte Inc | 0.1 | ||
| Brookdale Senior Living Inc | 0.0 | ||
| ISIS Pharmaceuticals Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | Eversept Generations Fund LP | [2021-03-24] | 322.6 M | 470.5 M |
| Filed 2025-10-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Eversept ELS Master Fund LP | [2018-03-29] | 41.8 M | 97.9 M |
| Filed 2025-10-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Eversept Global Healthcare Fund LP | [2016-03-31] | 110.2 M | 1,745.7 M |
| Filed 2025-10-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Commission $499,813 · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 1 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 8 | 2.6 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 9 | 2.7 |
| By Discretionary | ||
| Discretionary | 9 | 2.7 |
| Non-Discretionary | 0 | 0.0 |
| Total | 9 | 2.7 |
| By Non-United States Persons | ||
| Non-United States Persons | 1.1 | |
| United States Persons | 1.6 | |
| Total | 9 | 2.7 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Scott Lennon | Director | 163 | 37 | |
| Richard Ruffer | Director | 422 | 15 | |
| Deanna Derrick | Director | 40 | 15 | |
| Kamran Moghtaderi | Director, Executive Officer | 5 | 3 | |
| Eversept Partners LP | Promoter | 4 | 3 | |
| Eversept Partners LLC | Promoter | 2 | 2 | |
| Eversept GP II LLC | Promoter | 1 | 1 | |
| Eversept GP III LP | Executive Officer | 1 | 1 | |
| Eversept GP III LLC | Promoter | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001697013] | |
| SC 13G | [0001697013] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Eversept Partners LP | Zimvie Inc | [2024-11-14] |
| Eversept Partners LP | Cabaletta Bio Inc | [2022-08-22] |
| Eversept Partners LP | Community Health Systems Inc | [2022-08-15] |
| Eversept Partners LP | Teligent Inc | [2019-09-06] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| LEI | 549300X2D2KLB2XLNK52 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Mangrove Partners IM LLC
✚
|
CT | 2,705.9 M |
|
1Sharpe Capital LLC
✚
|
CA | 2,700.3 M |
|
Hook Mill Capital Partners LP
✚
|
NY | 2,698.0 M |
|
Advanced Portfolio Management LLC
✚
|
NY | 2,697.1 M |
|
Gobi Capital LLC
✚
|
CA | 2,689.4 M |
|
Cadian Capital Management LP
✚
|
NY | 2,680.0 M |
|
Variant Investments LLC
✚
|
OR | 2,638.5 M |
|
Quinn Opportunity Partners LLC
✚
|
VA | 2,614.0 M |
|
Divisadero Street Capital Management LP
✚
|
FL | 2,611.3 M |
|
LCG Associates Inc
✚
|
GA | 2,608.7 M |